SHANDONG XINHUA(00719),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

00719 SHANDONG XINHUA

Market Closed 12-27 16:08:22

5.840

+0.000

0.00%

High5.890	Low5.810	Vol986.00K
Open5.840	D1 Closing5.840	Amplitude1.37%
Mkt Cap3.99B	Tradable Cap1.14B	Total Shares682.41M
T/O5.76M	T/O Rate0.51%	Tradable Shares195.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"00719","market":"HK","secType":"STK","nameCN":"SHANDONG XINHUA","latestPrice":5.84,"timestamp":1735286902011,"preClose":5.84,"halted":0,"volume":986000,"delay":0,"floatShares":195000000,"shares":682407635,"eps":0.7830899258839512,"marketStatus":"Market Closed","change":0,"latestTime":"12-27 16:08:22","open":5.84,"high":5.89,"low":5.81,"amount":5763340,"amplitude":0.013699,"askPrice":5.85,"askSize":84000,"bidPrice":5.84,"bidSize":2000,"shortable":0,"etf":0,"ttmEps":0.6917279633921988,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1735522200000},"marketStatusCode":7,"adr":0,"listingDate":851961600000,"exchange":"SEHK","adjPreClose":5.84,"dividendRate":0.050089,"openAndCloseTimeList":[[1735263000000,1735272000000],[1735275600000,1735286400000]],"volumeRatio":1.103231,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"000756","market":"SZ","secType":"STK","nameCN":"Shandong Xinhua Pharmaceutical Company Limited","latestPrice":16.59,"timestamp":1735282800000,"preClose":16.38,"halted":0,"volume":11589700,"delay":0,"premium":"-66.90"}},"requestUrl":"/m/hq/s/00719/wiki","defaultTab":"wiki","newsList":[{"id":"2490505002","title":"Shandong Xinhua Pharmaceutical Eyes Stake in Nutritional Oil Refining Firm","url":"https://stock-news.laohu8.com/highlight/detail?id=2490505002","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490505002?lang=en_us&edition=fundamental","pubTime":"2024-12-10 15:03","pubTimestamp":1733814220,"startTime":"0","endTime":"0","summary":"Shandong Xinhua Pharmaceutical  entered into a letter of intent with NovoSana  to potentially acquire up to 75% equity interest in NovoSana , a Monday bourse filing said.Upon completion of the Proposed Transaction, the Target Company will become a holding subsidiary of the Company that will be consolidated into the financial statements of the Group.The pharmaceutical and chemical products company intends to accelerate its involvement in the fish oil sector through the acquisition.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["00719","BK1515","BK1191"],"gpt_icon":0},{"id":"2488991480","title":"Shandong Xinhua Pharmaceutical Unit's Infection Drug Passes Chinese Regulator's Consistency Evaluation","url":"https://stock-news.laohu8.com/highlight/detail?id=2488991480","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488991480?lang=en_us&edition=fundamental","pubTime":"2024-12-03 18:00","pubTimestamp":1733220007,"startTime":"0","endTime":"0","summary":"Shandong Xinhua Pharmaceutical  unit Shandong Zibo Xincat Pharmaceutical recently obtained approval of azithromycin for suspension from China's National Medical Products Administration after it passed the regulator's quality and efficacy consistency evaluation, a Tuesday bourse filing said.Azithromycin is a macrolide antibiotic suitable for the treatment of mild-to-moderate infections caused by certain designated microbial sensitive strains, according to the pharmaceuticals and chemical products company.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0164","00719","BK1515","BK1191","000756","BK0239"],"gpt_icon":0},{"id":"2486025175","title":"Shandong Xinhua Pharmaceutical Gets Marketing Go-Ahead for Hyperphosphatemia Drug from FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2486025175","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486025175?lang=en_us&edition=fundamental","pubTime":"2024-11-26 17:01","pubTimestamp":1732611697,"startTime":"0","endTime":"0","summary":"Shandong Xinhua Pharmaceutical  recently received a drug registration approval letter for its sevelamer carbonate from the US Food and Drug Administration, a Monday Hong Kong bourse filing said.The marketing of sevelamer carbonate  has been approved following the completion of a review of the relevant drug master file.Sevelamer carbonate is used to control hyperphosphatemia in adult patients with chronic kidney disease who are undergoing dialysis.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1515","BK1191","BK0164","00719","000756","BK0239"],"gpt_icon":0},{"id":"2482095092","title":"Shandong Xinhua Pharmaceutical Gets Drug Registration Certificate for Hyperuricemia Drug by Chinese Regulator","url":"https://stock-news.laohu8.com/highlight/detail?id=2482095092","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482095092?lang=en_us&edition=fundamental","pubTime":"2024-11-11 18:36","pubTimestamp":1731321398,"startTime":"0","endTime":"0","summary":"Shandong Xinhua Pharmaceutical  unit Shandong Zibo Xincat Pharmaceutical recently received a drug registration certificate approved by China's National Medical Products Administration for its febuxostat tablets, a Monday bourse filing said.Febuxostat is suitable for the long-term treatment of hyperuricemia in gout patients.Hong Kong-listed shares of the pharmaceutical company closed over 1% lower on Monday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0164","00719","BK1515","BK1191","000756","BK0239"],"gpt_icon":0},{"id":"2481575042","title":"Xinhua Pharma's Calcium Deficiency Drug Gets Generic Status in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2481575042","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481575042?lang=en_us&edition=fundamental","pubTime":"2024-11-05 18:58","pubTimestamp":1730804291,"startTime":"0","endTime":"0","summary":"Shandong Xinhua Pharmaceutical's  calcium gluconate passed the consistency of quality and efficacy evaluation for generic drugs in China.The drug is indicated for treating hand-foot weakness caused by calcium deficiency, acute hypocalcemia, allergic diseases, relief from fluorosis, and cardiac resuscitation, among other conditions.The pharmaceuticals and chemical products company's shares closed over 3% higher on Tuesday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1515","BK1191","BK0164","00719","000756","BK0239"],"gpt_icon":0},{"id":"2480303096","title":"Shandong Xinhua Pharmaceutical Unit's Antibiotic Passes China Generics Evaluation","url":"https://stock-news.laohu8.com/highlight/detail?id=2480303096","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480303096?lang=en_us&edition=fundamental","pubTime":"2024-11-04 19:08","pubTimestamp":1730718527,"startTime":"0","endTime":"0","summary":"Shandong Xinhua Pharmaceutical  subsidiary Shandong Zibo Xincat Pharmaceutical's cefuroxime axetil dispersible tablets passed China's generics consistency evaluation, according to a Monday filing with the Hong Kong Exchange.The tablets are antibiotics indicated for the treatment of bacterial infections causing acute tonsillitis, pharyngitis and acute bacterial sinusitis, otitis media or middle ear infection, gonorrhea, among other infections, the filing said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1515","BK1191","BK0164","BK0239","000756","00719"],"gpt_icon":0},{"id":"2480377505","title":"Chinese Regulator Green Lights Shandong Xinhua Pharmaceutical's Marketing Application for Pain Relief Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2480377505","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480377505?lang=en_us&edition=fundamental","pubTime":"2024-11-04 18:11","pubTimestamp":1730715109,"startTime":"0","endTime":"0","summary":"Shandong Xinhua Pharmaceutical's  marketing application for pentazocine has been approved by China's National Medical Products Administration, a Monday bourse filing said.Pentazocine, which was developed by Sterling Winslip, now Sanofi, in the US and has been registered and China and abroad, is a kind of refined hemp drug use for pain relief, including cancer, traumatic, and postoperative pain.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","BK0164","00719","000756","BK1191","BK1515"],"gpt_icon":0},{"id":"2479138212","title":"Shandong Xinhua Pharmaceutical's Attributable Profit Falls 12% in January-September","url":"https://stock-news.laohu8.com/highlight/detail?id=2479138212","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479138212?lang=en_us&edition=fundamental","pubTime":"2024-10-30 12:21","pubTimestamp":1730262075,"startTime":"0","endTime":"0","summary":"Shandong Xinhua Pharmaceutical  reported a net profit attributable to the shareholders of 344.1 million yuan for the first nine months of the year, a decrease of 12.2% compared with 392.0 million yuan a year ago.Earnings per share were 0.50 yuan, down from 0.57 yuan in the year-ago period, according to a Tuesday filing with the Hong Kong Stock Exchange.The company's gross revenue stood at 6.73 billion yuan, a 3.6% increase compared with 6.50 billion yuan a year earlier.The company's Hong Kong-listed shares were down 3% in the recent trading, while its Chinese shares were down 2%.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["000756","BK1515","BK0239","BK1191","BK0164","00719"],"gpt_icon":0},{"id":"2478103950","title":"Shandong Xinhua Pharmaceutical Gets FDA Approval for Hyperphosphatemia Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2478103950","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478103950?lang=en_us&edition=fundamental","pubTime":"2024-10-28 18:44","pubTimestamp":1730112271,"startTime":"0","endTime":"0","summary":"Shandong Xinhua Pharmaceutical  has received an approval letter from the FDA for its abbreviated new drug application for its sevelamer carbonate tablets, a Monday bourse filing said.The tablets are used to control hyperphosphatemia in adult patients with chronic kidney disease undergoing dialysis.Hong Kong- and China-listed shares of the pharmaceutical company closed 2% higher on Monday.Price : $6.21, Change: $+0.12, Percent Change: +1.97%","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["00719","BK0164","BK4585","BK1515","HKD","BK0239","000756","BK4526","BK4588","BK1191","BK4023"],"gpt_icon":0},{"id":"2472360302","title":"Shandong Xinhua Pharmaceutical (HKG:719) stock performs better than its underlying earnings growth over last five years","url":"https://stock-news.laohu8.com/highlight/detail?id=2472360302","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472360302?lang=en_us&edition=fundamental","pubTime":"2024-10-01 07:48","pubTimestamp":1727740106,"startTime":"0","endTime":"0","summary":"When we invest, we're generally looking for stocks that outperform the market average. And while active stock picking...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-719/shandong-xinhua-pharmaceutical-shares/news/shandong-xinhua-pharmaceutical-hkg719-stock-performs-better","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["00719"],"gpt_icon":0},{"id":"2464846621","title":"Shandong Xinhua Pharmaceutical Gets Chemical Listing Approval for GERD Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2464846621","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2464846621?lang=en_us&edition=fundamental","pubTime":"2024-09-03 13:30","pubTimestamp":1725341441,"startTime":"0","endTime":"0","summary":"Shandong Xinhua Pharmaceutical (SHE:000756, HKG:0719) received approval for listing of chemical APIs for its esomeprazole magnesium drug from China's National Medical Product Administration, according","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","BK1515","HKD","BK4526","BK0239","BK0164","BK4023","BK1191","000756","BK4585","00719"],"gpt_icon":0},{"id":"2464831364","title":"Shandong Xinhua Pharmaceutical Gets Marketing Go-Ahead for Reflux Disease Drug in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2464831364","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2464831364?lang=en_us&edition=fundamental","pubTime":"2024-09-02 20:41","pubTimestamp":1725280880,"startTime":"0","endTime":"0","summary":"Shandong Xinhua Pharmaceutical  has obtained marketing approval for its esomeprazole magnesium drug from China's National Medical Product Administration, a Monday bourse filing said.Esomeprazole magnesium is used to treat reflux disease, according to the pharmaceutical company.Hong Kong- and China-listed shares of the company closed 1% and 2% lower, respectively, on Monday.Price : $5.28, Change: $-0.060, Percent Change: -1.12%","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["000756","BK4526","BK0239","BK4023","BK4585","HKD","00719","BK1515","BK0164","BK4588","BK1191"],"gpt_icon":0},{"id":"2462962208","title":"Shandong Xinhua Pharmaceutical's Profit Down Slightly in H1","url":"https://stock-news.laohu8.com/highlight/detail?id=2462962208","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2462962208?lang=en_us&edition=fundamental","pubTime":"2024-08-26 18:16","pubTimestamp":1724667376,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_live","symbols":["BK4585","BK1191","BK4588","BK1515","BK4023","HKD","BK0239","00719","000756","BK4526","BK0164","SHE"],"gpt_icon":0},{"id":"2462962170","title":"Shandong Xinhua Pharmaceutical's Profit Down Slightly in H1","url":"https://stock-news.laohu8.com/highlight/detail?id=2462962170","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2462962170?lang=en_us&edition=fundamental","pubTime":"2024-08-26 18:16","pubTimestamp":1724667376,"startTime":"0","endTime":"0","summary":"Shandong Xinhua Pharmaceutical  saw a 1.6% decline in attributable profit for the six months ended June 30 to 265.4 million yuan from 269.8 million yuan a year prior, an Aug. 22 bourse filing said.Earnings per share stood at 0.38 yuan during the interim period, down from 0.39 yuan in the first half of 2023.Operating revenue for the pharmaceutical firm rose by 1.3% to 4.73 billion yuan in H1 from 4.67 billion yuan during the corresponding period last year.The company has recommended an interim dividend of 0.25 yuan per 10 shares for the half year.Hong Kong-listed shares of the company closed over 1% higher on Monday.Price : $5.34, Change: $+0.060, Percent Change: +1.14%","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["HKD","BK4585","BK1515","BK4526","BK1191","BK0164","00719","BK4023","000756","BK0239","BK4588"],"gpt_icon":0},{"id":"2461557806","title":"Xinhua Pharmaceutical's Alzheimer's Drug Completes Phase I Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2461557806","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2461557806?lang=en_us&edition=fundamental","pubTime":"2024-08-23 17:15","pubTimestamp":1724404519,"startTime":"0","endTime":"0","summary":"Shandong Xinhua Pharmaceutical  said its Alzheimer's drug OAB-14 completed Phase I testing and is expected to advance to Phase II within the year.The drug was manufactured by Shandong Zibo Xincat Pharmaceutical, a unit of the company. It is used to treat mild to moderate Alzheimer's disease, according to a Thursday filing with the Hong Kong Exchange.Price : $5.28, Change: $-0.050, Percent Change: -0.94%","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","00719","BK1191","BK0164","BK0239","BK4023","BK1515","HKD","000756","BK4585","BK4526"],"gpt_icon":0},{"id":"2461557536","title":"Xinhua Pharmaceutical's Alzheimer's Drug Completes Phase I Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2461557536","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2461557536?lang=en_us&edition=fundamental","pubTime":"2024-08-23 17:15","pubTimestamp":1724404519,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_live","symbols":["BK0239","BK4526","BK4585","SHE","000756","BK4023","BK0164","BK4588","00719","HKD","BK1191","BK1515"],"gpt_icon":0},{"id":"2453973036","title":"Shandong Xinhua Pharmaceutical CFO Resigns, Replacement Named","url":"https://stock-news.laohu8.com/highlight/detail?id=2453973036","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2453973036?lang=en_us&edition=fundamental","pubTime":"2024-07-22 15:38","pubTimestamp":1721633931,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_live","symbols":["BK1515","000756","HKD","BK1191","00719","BK0239","SHE","BK4023","BK4588","BK4585","BK0164","BK4526"],"gpt_icon":0},{"id":"2453173053","title":"Shandong Xinhua Pharmaceutical CFO Resigns, Replacement Named","url":"https://stock-news.laohu8.com/highlight/detail?id=2453173053","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2453173053?lang=en_us&edition=fundamental","pubTime":"2024-07-22 15:38","pubTimestamp":1721633931,"startTime":"0","endTime":"0","summary":"Shandong Xinhua Pharmaceutical  CFO Cheng Yanling resigned due to personal reasons, according to a Saturday filing on the Shanghai Stock Exchange.Cao Xu was named CFO of the company, succeeding Cheng. Both changes were effective July 19.The company's shares were up by around 1% in Hong Kong and Shenzhen recently.Price : $5.23, Change: $+0.03, Percent Change: +0.58%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1515","000756","HKD","BK1191","00719","BK0239","BK4023","BK4588","BK4585","BK0164","BK4526"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.xhzy.com","stockEarnings":[{"period":"1week","weight":0.0017},{"period":"1month","weight":0.0121},{"period":"3month","weight":0.0228},{"period":"6month","weight":0.1473},{"period":"1year","weight":0.0926},{"period":"ytd","weight":0.07}],"compareEarnings":[{"period":"1week","weight":0.0187},{"period":"1month","weight":0.0249},{"period":"3month","weight":-0.0263},{"period":"6month","weight":0.1339},{"period":"1year","weight":0.1788},{"period":"ytd","weight":0.1785}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"SHANDONG XINHUA PHARMACEUTICAL COMPANY LIMITED is a China-based company principally engaged in the development, production and distribution of chemical bulk drugs, preparations and medical intermediates. The Company’s main products include metamizole sodium, caffeine, aminopyrine, aspirin, hydrocortisone, pipemidic acid, ibuprofen, L-dopa, pipemidic acid tablets, compound liquorice tablets and nimodipine tablets. The Company distributes its products in domestic market and to overseas markets, including the Americas, Europe and others.","yearOnYearQuotes":[{"month":1,"riseRate":0.607143,"avgChangeRate":-0.014683},{"month":2,"riseRate":0.821429,"avgChangeRate":0.107857},{"month":3,"riseRate":0.428571,"avgChangeRate":-0.005849},{"month":4,"riseRate":0.75,"avgChangeRate":0.110341},{"month":5,"riseRate":0.321429,"avgChangeRate":-0.003589},{"month":6,"riseRate":0.428571,"avgChangeRate":-0.006604},{"month":7,"riseRate":0.571429,"avgChangeRate":0.006209},{"month":8,"riseRate":0.296296,"avgChangeRate":-0.041364},{"month":9,"riseRate":0.37037,"avgChangeRate":-0.017083},{"month":10,"riseRate":0.464286,"avgChangeRate":0.010896},{"month":11,"riseRate":0.535714,"avgChangeRate":0.01142},{"month":12,"riseRate":0.607143,"avgChangeRate":0.027737}],"exchange":"SEHK","name":"SHANDONG XINHUA","nameEN":"SHANDONG XINHUA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"SHANDONG XINHUA(00719),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest SHANDONG XINHUA(00719) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"SHANDONG XINHUA,00719,SHANDONG XINHUA股票,SHANDONG XINHUA股票老虎,SHANDONG XINHUA股票老虎国际,SHANDONG XINHUA行情,SHANDONG XINHUA股票行情,SHANDONG XINHUA股价,SHANDONG XINHUA股市,SHANDONG XINHUA股票价格,SHANDONG XINHUA股票交易,SHANDONG XINHUA股票购买,SHANDONG XINHUA股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"SHANDONG XINHUA(00719),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest SHANDONG XINHUA(00719) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}